Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Biorasi.

    Client Virtual Booth

    BIORASI

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Biorasi
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    18851 NE 29th Ave, Suite 800, Aventura, Florida 33180
    Telephone
    Telephone
    +1 786-388-0700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://biorasi.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biorasi-llc/
    Twitter
    Twitter
    https://twitter.com/Biorasi

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Tria...

    Details:

    ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.


    Lead Product(s): ALZN002

    Therapeutic Area: Neurology Product Name: ALZN002

    Highest Development Status: IND EnablingProduct Type: Vaccine

    Recipient: Alzamend Neuro

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership January 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

    Details:

    Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of adult donors. Longeveron is advancing Lomecel-B through clinical trials in 3 indications: Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty.


    Lead Product(s): Allogeneic Bone Marrow-derived Medicinal Signaling Cells

    Therapeutic Area: Neurology Product Name: Lomecel-B

    Highest Development Status: Phase IIProduct Type: Cell and Gene therapy

    Recipient: Longeveron

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 10, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally

    Details:

    Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).


    Lead Product(s): Minocycline Hydrochloride,EDTA acid,Ethanol

    Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Citius Pharmaceuticals

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 06, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell™ Universal Do...

    Details:

    JadiCell (mesenchymal stem cells), was shown to be 100% effective in saving the lives of COVID-19 patients under age of 85 in a double-blind, randomized, placebo controlled clinical trial with patients in the ICU on a ventilator.


    Lead Product(s): Mesenchymal Stem Cells

    Therapeutic Area: Infections and Infectious Diseases Product Name: JadiCell

    Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

    Recipient: Therapeutic Solutions

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 02, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search